Safety and efficacy of pembrolizumab combined with paclitaxel and cisplatin as a neoadjuvant treatment for locally advanced resectable (stage III) esophageal squamous cell carcinoma (Keystone-001): Interim analysis of a prospective, single-arm, single-center, phase II trial

被引：15

作者：

Shang, X. ^{[1
]}

Zhang, C. ^{[1
]}

Zhao, G. ^{[2
]}

Zhang, W. ^{[3
]}

Liu, L. ^{[3
]}

Duan, X. ^{[1
]}

Yue, J. ^{[1
]}

Ma, Z. ^{[1
]}

Chen, C. ^{[1
]}

Meng, B. ^{[2
]}

Ren, X. ^{[3
]}

Jiang, H. ^{[1
]}

机构：

[1] Tianjin Med Univ, Canc Inst & Hosp, Dept Minimally Invas Esophageal Surg, Tianjin, Peoples R China

[2] Tianjin Med Univ, Canc Inst & Hosp, Dept Pathol, Tianjin, Peoples R China

[3] Tianjin Med Univ, Canc Inst & Hosp, Dept Immunol, Tianjin, Peoples R China

来源：

ANNALS OF ONCOLOGY | 2021年 / 32卷

关键词：

D O I：

10.1016/j.annonc.2021.10.218

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA3

引用

页码：S1428 / S1429

页数：2

共 50 条

[1] Safety and effectiveness of pembrolizumab combined with paclitaxel and cisplatin as neoadjuvant therapy followed by surgery for locally advanced resectable (stage III) esophageal squamous cell carcinoma: a study protocol for a prospective, single-arm, single-center, open-label, phase-II trial (Keystone-001)
Shang, Xiaobin
Zhao, Gang
Liang, Fei
Zhang, Chen
Zhang, Weihong
Liu, Liang
Li, Runmei
Duan, Xiaofeng
Ma, Zhao
Yue, Jie
Chen, Chuangui
Meng, Bin
Ren, Xiubao
Jiang, Hongjing
ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (04)
[2] A prospective study of neoadjuvant pembrolizumab plus chemotherapy for resectable esophageal squamous cell carcinoma: The Keystone-001 trial
Shang, Xiaobin
Xie, Yongjie
Yu, Jinpu
Zhang, Chen
Zhao, Gang
Liang, Fei
Liu, Liang
Zhang, Weihong
Li, Runmei
Yu, Wenwen
Yue, Jie
Chen, Chuangui
Duan, Xiaofeng
Ma, Zhao
Chen, Zuoyu
Xiong, Yanjuan
Yang, Fan
Xiao, Jianyu
Zhang, Rui
Liu, Pengpeng
Cheng, Yanan
Cao, Fuliang
Guo, Feng
Liu, Guoyan
Meng, Bin
Zhou, Dejun
Sun, Yan
Ren, Xiubao
Yu, Jun
Hao, Jihui
Jiang, Hongjing
CANCER CELL, 2024, 42 (10)
[3] Neoadjuvant anlotinib combined with penpulimab for resectable locally advanced esophageal squamous cell carcinoma (ESCC): A prospective, single-arm, phase II trial.
Chen, Yueyun
Ding, Zhen-Yu
Yuan, Yong
Yang, Yu-Shang
Lin, Zhen
Tian, Jiangfang
Liu, Ting
Yue, Zheng
Shi, Hua-Shan
Hu, Yang
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 352 - 352
[4] Safety and efficacy of camrelizumab combined with radiotherapy as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma: a prospective single-arm phase II clinical trial protocol
Chen, Maohui
Huang, Yizhou
Zhang, Shuliang
Zeng, Taidui
Huang, Guanglei
Chen, Chun
Zheng, Bin
TRIALS, 2023, 24 (01)
[5] Safety and efficacy of camrelizumab combined with radiotherapy as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma: a prospective single-arm phase II clinical trial protocol
Maohui Chen
Yizhou Huang
Shuliang Zhang
Taidui Zeng
Guanglei Huang
Chun Chen
Bin Zheng
Trials, 24 (1)
[6] Preoperative pembrolizumab plus chemotherapy for resectable esophageal squamous cell carcinoma (ESCC): The phase II Keystone-001 trial
Jiang, H.
Shang, X.
Xie, Y.
Zhao, G.
Zhang, C.
Zhang, W.
Liu, L.
Li, R.
Yue, J.
Chen, C.
Duan, X.
Ma, Z.
Sun, Y.
Yu, J.
Ren, X.
ANNALS OF ONCOLOGY, 2023, 34 : S872 - S873
[7] Toripalimab combined with docetaxel and cisplatin neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma: a single-center, single-arm clinical trial (ESONICT-2)
Gao, Lei
Lu, Jieming
Zhang, Peipei
Hong, Zhi-Nuan
Kang, Mingqiang
JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2022, 13 (02) : 478 - 487
[8] Camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma (ESCC): A single-arm, phase II trial
Gong, Lei
Yang, Yueyang
Zhang, Hongdian
Qiao, Yufeng
Wang, Haitong
Ren, Peng
Tang, Peng
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[9] Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma
Liu, Jun
Yang, Yang
Liu, Zhichao
Fu, Xiaolong
Cai, Xiaoyue
Li, Hongxuan
Zhu, Li
Shen, Yan
Zhang, Hong
Sun, Yifeng
Chen, Hezhong
Yu, Bentong
Zhang, Renquan
Shao, Jinchen
Zhang, Ming
Li, Zhigang
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (03)
[10] Neoadjuvant pembrolizumab/nab-paclitaxel/cisplatin in patients with locally advanced head and neck squamous cell carcinoma: A single-arm phase II study
Zhang, Siyi
Ma, Haiqing
Zhan, Jiandong
Zhu, Lijun
Zhang, Hong-Dan
Du, Shasha
Dong, Qiumei
Wang, Guangyi
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

← 1 2 3 4 5 →